一个随机对照试验的贝他美沙在疲劳的病人与晚期癌症
Kikuko Miyazaki1, Masayuki Ikenaga2, Tosiya Sato3
1Department of Health Informatics (K.M., T.N.), Kyoto University School of Public Health, Kyoto, Japan.
Journal of pain and symptom management
|February 8, 2024
概括
这项研究发现,每天服用4毫克贝他他并没有根据主要终点显著降低晚期癌症患者的疲劳,但在次要测量上显示出改善. 需要进一步的研究来证实它在治疗癌症相关疲劳方面的有效性.
科学领域:
- 在瘤学瘤学.
- 抚慰性护理是一种缓解性护理.
- 临床药理学 临床药理学
背景情况:
- 疲劳是晚期癌症患者中普遍存在和使人衰弱的症状.
- 皮质类固醇对癌症疲劳的疗效以前已经被研究过,主要是在西方人群中.
研究的目的:
- 评估4毫克贝塔梅他在缓解晚期癌症的日本患者疲劳方面的有效性.
- 评估贝塔梅他对该患者群体生活质量的影响.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的试验.
- 符合条件的晚期癌症患者 (ECOG PS 2-3,1-2个月存活率) 每天接受4mg贝他美沙或安慰剂,持续7天.
- 使用EORTC QLQ-C15-PAL疲劳分量表和数值评分量表 (NRS) 来评估疲劳.
主要成果:
- 主要终点,EORTC QLQ-C15-PAL疲劳分量表,显示贝他美和安慰剂之间没有统计学上显著的差异 (P = 0.178).
- 二级终点,疲劳的NRS,证明了对贝他美沙的统计学显著改善 (P = 0.048).
- 在贝塔梅他组中,在情绪功能,食欲和整体健康方面观察到轻微的改善.
结论:
- 贝塔美沙4mg/d没有达到统计学意义的疲劳减轻根据主要终点 (EORTC QLQ-C15-PAL).
- 使用二次终点 (NRS) 观察到对疲劳的统计学显著影响.
- 在接近生命终点的晚期癌症患者中,贝他美可能为特定的生活质量方面提供一些好处.
相关概念视频
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...